How to access Zolgensma from India — the named-patient coordination pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian child with biallelic SMN1 mutations and a clinical or pre-symptomatic diagnosis of spinal muscular atrophy (SMA) — typically under two years of age and meeting weight and serology criteria — may be evaluated by their treating paediatric neurologist for Zolgensma (onasemnogene abeparvovec). Zolgensma is FDA-approved, developed by Novartis Gene Therapies (formerly AveXis), and is a one-time intravenous AAV9-based gene therapy delivering a functional SMN1 gene. Because Zolgensma is a single-dose therapy with a narrow eligibility window and serology gating, access involves a coordinated pathway rather than a routine prescription.

This guide explains the legal and operational pathway, what your paediatric neurologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Zolgensma is a one-time intravenous infusion of a recombinant AAV9 vector carrying the human SMN1 gene, addressing the underlying genetic cause of SMA. Key eligibility elements:

• Biallelic SMN1 mutations — confirmed on molecular testing.
• Age — current FDA labelling covers paediatric patients under two years at time of dosing; timing matters because motor-neuron loss is progressive.
• Weight — dosing is weight-based; the supplied product and practical handling become rate-limiting for heavier children.
• Anti-AAV9 serology — patients with elevated anti-AAV9 antibody titres are ineligible because the vector will be neutralised; pre-dose serology is mandatory.
• Prior nusinersen or risdiplam exposure — not a contraindication but relevant to the overall treatment plan.
• Hepatic status — baseline liver function is required; corticosteroids are given around the infusion to mitigate transaminitis.

Administration is at a gene-therapy-qualified paediatric centre with capability for AAV infusion, cardiac and hepatic monitoring, and intensive supportive care as needed. Your paediatric neurologist will confirm the eligibility matrix and identify a qualified administering facility.

Is Zolgensma legally accessible for Indian patients?

Yes — via the Central Drugs Standard Control Organisation (CDSCO) named-patient / personal-use import framework, with the operational constraint that administration must occur at a gene-therapy-qualified centre. The mechanism permits a treating physician to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.

For Zolgensma specifically, the application emphasises the administering centre's gene-therapy capability, the narrow eligibility window, and the cold-chain and handling protocols.

How the pathway works, step by step

1. Consultation with your paediatric neurologist. SMN1 confirmation, age/weight eligibility, anti-AAV9 serology, hepatic and cardiac baseline, clinical rationale letter.
2. Administering-centre identification. A gene-therapy-qualified paediatric centre is nominated with cardiac, hepatic, and intensive-care capability for AAV infusion and post-infusion monitoring.
3. CDSCO named-patient application. Your physician files the dossier including rationale, patient reference, centre capability attestation, and single-dose plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner and, where applicable, directly with the manufacturer's global access programme, to secure Zolgensma under DSCSA chain-of-custody.
5. Cold-chain shipment. Zolgensma ships with validated ultra-cold-chain logistics to the administering hospital pharmacy timed to the scheduled infusion date.
6. Infusion and monitoring. The gene-therapy centre administers the one-time IV infusion with peri-infusion corticosteroids, hepatic monitoring, cardiac surveillance, and structured follow-up per FDA labelling.

What documentation your physician needs

• Clinical rationale letter confirming SMA diagnosis, SMN1 biallelic status, age and weight, anti-AAV9 serology, hepatic and cardiac baseline, and Zolgensma as the indicated treatment
• Verification of NMC / MCI registration
• SMN1 molecular-testing report
• Anti-AAV9 antibody titre
• Baseline hepatic panel, cardiac assessment (ECG / echo), and weight documentation
• Identification of the gene-therapy-qualified administering centre
• Peri-infusion corticosteroid and monitoring plan

Reserve Meds provides a coordination kit that bundles the CDSCO and administering-centre templates reviewers expect to see for paediatric gene-therapy named-patient files.

Costs and timing

Zolgensma's US list price for the one-time product sits in an indicative 2026 range of roughly USD 2.1–2.5 million. Total cost of care — including the administering centre's infusion, monitoring, and supportive care — adds incremental local-facility cost. International logistics (ultra-cold chain), CDSCO documentation handling, importer-of-record fees, and concierge coordination add further cost. Reserve Meds issues a transparent quote at the start of intake, reflecting that Zolgensma is a one-time therapy rather than a recurring-dose product. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — from intake to infusion is typically 6–12 weeks, driven by serology, centre scheduling, and cold-chain logistics alignment.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly. Paediatric SMA cases with narrow age-window eligibility are routinely triaged as urgent.

A culturally-aware note: SMA diagnosis in India often comes late relative to the Zolgensma age-window, and families may face difficult sequencing decisions between Zolgensma, Spinraza, and Evrysdi. We work alongside your paediatric neurology team and never substitute for their clinical judgement on which therapy best fits your child.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner and, where applicable, manufacturer access-programme coordination, under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for CDSCO review, keyed to the paediatric gene-therapy rationale.
• Logistics. Validated ultra-cold-chain shipment to the administering centre, timed to the infusion schedule.
• Concierge case lead. A named point of contact for the family through pre-infusion workup, the infusion day, and structured follow-up.

What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the gene-therapy product, and we are not the administering centre. All clinical decisions remain with your paediatric neurologist and the administering gene-therapy centre. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

My child has already had Spinraza doses — are they still eligible? Prior nusinersen exposure is not a contraindication. Your neurologist decides sequencing; many children receive nusinersen before or after Zolgensma.

What if the anti-AAV9 titre is elevated? Current labelling excludes patients with elevated titres because the AAV9 vector will be neutralised. Your paediatric neurology team will discuss alternative SMA therapies (Spinraza, Evrysdi).

What about hepatotoxicity? Transaminitis is expected around the infusion and is managed with peri-infusion corticosteroids and close hepatic monitoring. Thrombotic microangiopathy and cardiac toxicity are rarer but serious risks the infusion centre monitors for.

Will insurance or philanthropic support cover this? Cash-pay is the default for named-patient imports. Several SMA philanthropic programmes and crowdfunding efforts have supported Indian Zolgensma cases; we supply documentation but do not manage funding directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026 for gene-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Zolgensma coordination.

Add me to the Zolgensma waitlist

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.